Establishment of AD model mice harboring novel pathogenic PS1 mutation presenting "Behavioral and Psychological Symptoms of Dementia"
Project/Area Number |
15K09840
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Psychiatric science
|
Research Institution | Sapporo Medical University |
Principal Investigator |
Kawamata Jun 札幌医科大学, 医学部, 准教授 (60360814)
|
Co-Investigator(Kenkyū-buntansha) |
下濱 俊 札幌医科大学, 医学部, 教授 (60235687)
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
Keywords | アルツハイマー病 / BPSD / プレセニリン1 / トランスジェニックマウス / CRISPR/Cas9 / アルツハイマー |
Outline of Final Research Achievements |
We report the familial Alzheimer pedigree carrying a novel mutation, three bases deletion, which results in one amino acid deletion of PS1 (Psen1 delta p.277). To establish the adequate animal model of AD especially presenting BPSD-like symptoms, we planned to make the transgenic mice harboring the mutation using CRISPR/Cas9 method. Even after injecting more than 200 times, no living mutant mouse was obtained. Remodeling guide RNA(crRNA) results in successfully establishing the transgenic mice, which will enable the neuropathological and behavioral analysis after aging of these transgenic mice, both heterozygote and possibly homozygote.
|
Report
(4 results)
Research Products
(6 results)
-
[Journal Article] Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.2017
Author(s)
Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group.(collaborators: Kawamata J.他)
-
Journal Title
Lancet Neurol.
Volume: 16
Issue: 12
Pages: 976-986
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
[Journal Article] Role of Suppressor of Cytokine Signaling 3 (SOCS3) in Altering Activated Microglia Phenotype in APPswe/PS1dE9 Mice.2017
Author(s)
Iwahara N, Hisahara S, Kawamata J, Matsumura A, Yokokawa K, Saito T, Fujikura M, Manabe T, Suzuki H, Matsushita T, Suzuki S, Shimohama S.
-
Journal Title
J Alzheimers Dis.
Volume: 55
Issue: 3
Pages: 1235-1247
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] Evaluation of oxidative stress in the brain of a transgenic mouse model of Alzheimer disease by in vivo electron paramagnetic resonance imaging.2015
Author(s)
Matsumura A, Emoto MC, Suzuki S, Iwahara N, Hisahara S, Kawamata J, Suzuki H,Yamauchi A, Sato-Akaba H, Fujii HG, Shimohama S.
-
Journal Title
Free Radic Biol Med.
Volume: 85
Pages: 165-173
DOI
Related Report
Peer Reviewed / Int'l Joint Research
-